

Changing Epidemiology of Community-Associated Methicillin-Resistant *Staphylococcus aureus* (CA-MRSA) in Canadian Hospitals from 2007-2012

K.A. NICHOL¹, H.J. ADAM^{1,2}, G.R. GOLDING^{2,3}, M. McCracken³, M. BAXTER², C. YACHISON⁴, P. LAGACÉ-WIENS^{1,2}, D.J. HOBAN^{1,2} and G.G. ZHANEL²
Diagnostic Services of Manitoba¹, University of Manitoba², National Microbiology Laboratory³, University of Winnipeg⁴,
Canadian Antimicrobial Resistance Alliance (CARA), Winnipeg, Manitoba, Canada

ABSTRACT

Background: As part of the CANWARD surveillance study, we compared the epidemiology of CA-MRSA and health care-associated (HA)-MRSA genotypes in Canadian hospitals.

Methods: Between 2007 and 2012, 1391 MRSA were collected from patients attending tertiary-care medical centres across Canada. Susceptibility testing was performed by CLSI broth microdilution. Isolates were characterized by *spa* type, *agr* specificity group, SCCmec type and PCR of the Panton-Valentine leukocidin (PVL) gene. Detection of hVISA was performed by the Etest macromethod and confirmed by population analysis profile-area under the curve.

Results: The annual prevalence of MRSA genotypes is shown below.

MRSA Type	Study Year						P-value*
	2007	2008	2009	2010	2011	2012	
All MRSA (% of all <i>S. aureus</i>)	26.1	27.0	21.0	21.2	19.3	18.2	<0.0001
HA-MRSA (% of all MRSA)	79.2	69.1	65.5	58.7	59.7	54.4	<0.0001
CMRSA1 [USA600]	2.3	1.1	0	1.8	0.6	4.0	0.35
CMRSA2 [USA100/800]	64.9	56.3	58.6	49.8	55.8	43.2	<0.0001
CMRSA3/6	10.6	8.8	4.7	3.1	0.6	0	<0.0001
CMRSA4 [USA200]	0	0.4	0	0.9	0	0.8	0.25
CMRSA5 [USA500]	1.0	1.5	0	1.3	1.3	2.4	0.37
CMRSA8	0	0.7	1.7	1.8	1.3	4.0	0.0008
CMRSA9	0.3	0.4	0.4	0	0	0	1
CA-MRSA (% of all MRSA)	19.7	27.6	31.9	38.1	36.4	39.2	<0.0001
CMRSA7 [USA400]	6.5	5.5	8.2	6.7	7.8	12.0	0.06
CMRSA10 [USA300]	13.2	22.1	23.7	31.4	28.6	27.2	0.0005
Unique	1.0	3.3	2.6	3.1	3.9	6.4	0.0021

*P-value determined by Fisher's exact test comparing 2007 vs. 2012 data.

The majority of CA-MRSA were *agr* type I (76.6%) and SCCmec type IVa (98.1%) while most HA-MRSA were *agr* type II (83.9%) and SCCmec type II (81.5%). PVL was detected in 87.7% of CA-MRSA and 0.7% of HA-MRSA. Resistance rates (CA vs HA) were 65.0 vs 96.6% to ciprofloxacin, 73.8 vs 95.1% to clarithromycin, 13.1 vs 67.8% to clindamycin and 0.0 vs 11.1% to trimethoprim-sulfamethoxazole. MRSA were 100% susceptible to linezolid and telavancin and 99.9% susceptible to daptomycin and vancomycin. The hVISA phenotype was detected in 31.0% (9/29) of MRSA with a vancomycin MIC of 2 µg/mL. **Conclusions:** The most frequent CA-MRSA genotype was USA300 (CMRSA10) while USA100/800 (CMRSA2) was the predominant HA-MRSA genotype. Despite a decrease in the numbers of MRSA, the proportion of CA-MRSA in Canadian hospitals has risen significantly between 2007 and 2012.

BACKGROUND

Community-associated methicillin-resistant *Staphylococcus aureus* (CA-MRSA) account for an increasing proportion of MRSA isolates in hospitals and long-term care facilities across North America. While skin and soft tissue infections are the most common infections caused by CA-MRSA, invasive disease such as bacteremia associated with sepsis and necrotizing pneumonia can occur. The individuals most often affected by CA-MRSA typically lack established risk factors for MRSA acquisition/infection. CA-MRSA differ from health care-associated MRSA (HA-MRSA) in that they are generally more susceptible to a variety of non-beta-lactam antimicrobial agents. Of particular concern, however, is the emergence of isolates with reduced susceptibility or heterogeneous resistance to vancomycin, an important antimicrobial for the empiric treatment of severe infections. In addition, the majority of CA-MRSA strains harbor virulence determinants such as the Panton-Valentine leukocidin (PVL) as well as other toxins that may contribute to the increasing morbidity and mortality associated with CA-MRSA infections. The purpose of this study was to compare the demographics, antimicrobial susceptibilities and molecular epidemiology of community-associated and health care-associated MRSA genotypes in Canada from 2007 to 2012, inclusive.

ACKNOWLEDGEMENTS

The authors would like to thank the participating centres, investigators and laboratory site staff for their support. Financial support for the CANWARD study was provided in part by Abbott Laboratories, Astellas Pharma Canada Inc., Bayer Canada, Cubist, Merck Canada, Pfizer Canada Inc., Sunovion and Theravance.

MATERIALS & METHODS

Methicillin-Resistant *S. aureus* Isolates

1391 isolates of MRSA were collected between 2007 and 2012 as part of the ongoing CANWARD surveillance study assessing antibiotic resistance in Canadian hospitals. Isolates were received from tertiary-care medical centres (12 in 2007, 10 in 2008, 15 in 2009, 14 in 2010, 15 in 2011, and 12 in 2012) that were geographically distributed in a population-based fashion in 8 of the 10 Canadian provinces. All *S. aureus* were identified at the originating centre using local site criteria. Resistance to methicillin was confirmed at the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada) using the CLSI-approved disk diffusion method with cefoxitin, as well as by growth on MRSASelect chromogenic media.

Antimicrobial Susceptibility Testing

The *in vitro* activities of cefazolin, clarithromycin, clindamycin, ciprofloxacin, daptomycin, levofloxacin, linezolid, moxifloxacin, telavancin, tigecycline, trimethoprim-sulfamethoxazole and vancomycin were determined by broth microdilution in accordance with CLSI guidelines (M7-A9, 2012). MIC interpretive standards were defined according to CLSI breakpoints (M100-S22, 2012). The following interpretive breakpoints (FDA) were used: telavancin susceptible, ≤ 1 µg/ml; tigecycline susceptible, ≤ 0.5 µg/ml.

Molecular Characterization of MRSA

MRSA status was confirmed by real-time PCR of the *mecA* and *nuc* genes (McDonald et al. 2005. J. Clin. Microbiol. 43:6147-6149). This triplex PCR assay included primers for the detection of the *lukF-PV* and *lukS-PV* genes encoding the Panton-Valentine leukocidin (PVL) toxin (McDonald et al. 2005. J. Clin. Microbiol. 43:6147-6149). Multiplex PCR was used to identify accessory gene regulator (*agr*) specificity groups (Shopsin et al. 2003. J. Clin. Microbiol. 41:456-459) and the Staphylococcal Chromosome Cassette *mec* (SCCmec) element was also typed by multiplex PCR (Zhang et al. 2005. J. Clin. Microbiol. 43:5026-5033).

MRSA strains were characterized by staphylococcal protein A (*spa*) typing as previously described (Golding et al. 2008. Can. J. Infect. Dis. Med. Microbiol. 19:273-281). For the purpose of this study, community-associated (CA)-MRSA and healthcare-associated (HA)-MRSA were defined genotypically (ie. on the basis of their *spa* type) and not epidemiologically as per CDC criteria for distinguishing CA-MRSA from HA-MRSA, because epidemiologic information was not available. There has previously been shown to be good correlation between *spa* types and Canadian epidemic PFGE strain types CMRSA1-10 (Golding et al. 2008. Can. J. Infect. Dis. Med. Microbiol. 19:273-281), allowing for classification of strains as either CA-MRSA or HA-MRSA. Any MRSA with a *spa* type associated with a CMRSA7 (USA400) or CMRSA10 (USA300) genotype were labeled as CA-MRSA while all other *spa* types corresponding to a characterized epidemic type (eg. CMRSA1 [USA600], CMRSA2 [USA100/800], CMRSA4 [USA200], CMRSA5 [USA500], CMRSA3/6, CMRSA8, CMRSA9, etc.) were labeled as HA-MRSA. MRSA with a *spa* type not associated with one of the known Canadian epidemic types were labeled as unique (non-CMRSA).

Detection of Heterogeneous Vancomycin-Intermediate *S. aureus* (hVISA)

All MRSA isolates with a vancomycin MIC of 2 µg/ml (n=29) were screened for the presence of the hVISA phenotype using the Etest macromethod. A randomly selected subset of MRSA with vancomycin MICs of 1 µg/ml (n=230, 20%) and 0.5 µg/ml (n=31, 15%) were included for comparison. MRSA identified as hVISA by the Etest macromethod were further evaluated by population analysis profile-area under the curve (PAP-AUC). *S. aureus* reference strains Mu3 (ATCC 700698, hVISA), Mu50 (ATCC700699, VISA) and ATCC 29213 (vancomycin-susceptible *S. aureus*) were included as controls.

CONCLUSIONS

- Overall, 29.8% and 67.3% of MRSA strains from Canadian hospitals were identified by *spa* typing as CA-MRSA and HA-MRSA, respectively. The prevalence of CA-MRSA increased significantly from 19.7% in 2007 to 39.2% in 2012 while HA-MRSA decreased from 79.2% to 54.4% during this same period ($P < 0.0001$).
- CA-MRSA genotypes CMRSA7 (USA400) and CMRSA10 (USA300) represented 7.3% and 22.6% of all MRSA, respectively. The prevalence of CMRSA10 (USA300) increased significantly from 13.2% in 2007 to 27.2% in 2012 ($P < 0.0001$).
- CMRSA2 (USA100/800) was the predominant HA-MRSA genotype, accounting for 56.8% of all MRSA and 84.4% of HA-MRSA.
- The majority (87.7%) of CA-MRSA were PVL(+) whereas 99.3% of HA-MRSA were PVL(-).
- Most CA-MRSA belonged to *agr* type I (76.6%) or III (23.1%). The majority of HA-MRSA belonged to *agr* type I (15.1%) or II (83.9%).
- 98.1% of CA-MRSA carried SCCmec type IVa. Most HA-MRSA carried SCCmec type II (81.5%).
- CA-MRSA strains were more susceptible to clarithromycin, clindamycin, fluoroquinolones and trimethoprim-sulfamethoxazole than HA-MRSA.
- 1.0% of CA-MRSA had a vancomycin MIC of 2 µg/ml compared to 2.7% of HA-MRSA ($P=0.06$). Intermediate resistance (MIC, 4 µg/ml) to vancomycin was observed in one MRSA with a PVL-negative CMRSA2 (USA100/800) genotype. MRSA were 100% susceptible to linezolid and telavancin and 99.9% susceptible to daptomycin and vancomycin.
- Detection of hVISA by PAP-AUC was rare overall (3.4%), but was common in isolates with a vancomycin MIC of 2 µg/ml (31.0%).

RESULTS

Figure 1. Proportion of *S. aureus* strains identified as MSSA or MRSA.




Figure 2. Proportion of MRSA strains identified as CA-MRSA or HA-MRSA.




Table 1. Demographics of patients with MRSA infections.

Characteristic	CA-MRSA (n=415)	HA-MRSA (n=936)	Total (n=1391)
Sex, n (%)			
Male	237 (57.1)	568 (60.7)	822 (59.1)
Female	178 (42.9)	368 (39.3)	569 (40.9)
Mean age, years	41.6	64.9	57.2
Median age (range)	43 (1-95)	68 (1-105)	61 (1-105)
Age group, n (%)			
≤ 17	65 (15.7)	17 (1.8)	90 (6.5)
18-64	289 (69.6)	376 (40.2)	689 (49.5)
≥ 65	61 (14.7)	543 (58.0)	612 (44.0)
Region, n (%)			
West	250 (60.2)	255 (27.2)	521 (37.5)
Ontario	124 (29.9)	305 (32.6)	446 (32.1)
Quebec	17 (4.1)	298 (31.8)	320 (23.0)
Maritimes	24 (5.8)	78 (8.3)	104 (7.4)
Hospital ward type, n (%)			
Emergency room	152 (36.6)	145 (15.5)	309 (22.2)
Clinic/office	84 (20.2)	121 (12.9)	214 (15.4)
Intensive care unit	65 (15.7)	185 (19.8)	253 (18.2)
Medical/surgical ward	114 (27.5)	485 (51.8)	615 (44.2)
Infection site, n (%)			
Bloodstream	146 (35.2)	370 (39.5)	529 (38.0)
Respiratory tract	89 (21.4)	370 (39.5)	465 (33.4)
Urinary tract	2 (0.5)	44 (4.7)	47 (3.4)
Wounds/IV sites	178 (42.9)	152 (16.2)	350 (25.2)

Figure 3. Distribution of CA-MRSA and HA-MRSA PFGE epidemic types.




Figure 4. Distribution of PVL(+) and PVL(-) CA-MRSA and HA-MRSA.




Figure 5. Distribution of CA-MRSA and HA-MRSA *agr* specificity groups.




Figure 6. Distribution of CA-MRSA and HA-MRSA SCCmec types.




Table 3. Comparison of antibiotic resistance rates among CA-MRSA and HA-MRSA.

Antibiotic	CA-MRSA (n=415)			% of Isolates per Category		
	MIC ₅₀	MIC ₉₀	MIC Range	S	I	R
Cefazolin	16	64	1 - >128	-	-	100.0% ^a
Ciprofloxacin	16	>16	0.12 - >16	34.3%	0.7%	65.0%
Clarithromycin	>16	>16	≤ 0.25 - >16	26.0%	0.2%	73.8%
Clindamycin	≤ 0.25	>8	≤ 0.25 - >8	86.9%	0.0%	13.1%
Daptomycin	0.25	0.25	0.12 - 2	99.8%	-	0.2%
Levofloxacin	4	8	0.12 - >32	40.0%	0.0%	60.0%
Linezolid	2	2	1 - 4	100.0%	-	-
Moxifloxacin	2	2	≤ 0.06 - 16	35.7%	6.8%	57.5%
Telavancin	0.25	0.5	0.12 - 1	100.0%	-	-
Tigecycline	0.25	0.25	0.06 - 0.5	100.0%	-	-
TMP-SMX	≤ 0.12	≤ 0.12	≤ 0.12 - 2	100.0%	-	0.0%
Vancomycin	1	1	0.5 - 2	100.0%	0.0%	0.0%

^aBased on cefoxitin disk test.

Antibiotic	HA-MRSA (n=936)			% of Isolates per Category		
	MIC ₅₀	MIC ₉₀	MIC Range	S	I	R
Cefazolin	128	>128	1 - >128	-	-	100.0% ^a
Ciprofloxacin	>16	>16	0.25 - >16	3.4%	0.0%	96.6%
Clarithromycin	>16	>16	≤ 0.25 - >16	4.9%	0.0%	95.1%
Clindamycin	>8	>8	≤ 0.25 - >8	32.1%	0.1%	67.8%
Daptomycin	0.25	0.25	0.06 - 1	100.0%	-	-
Levofloxacin	>32	>32	0.12 - >32	2.9%	0.0%	97.1%
Linezolid	2	2	≤ 0.12 - 4	100.0%	-	0.0%
Moxifloxacin	8	>16	≤ 0.06 - >16	3.5%	0.2%	96.3%
Telavancin	0.25	0.5	≤ 0.06 - 1	100.0%	-	-
Tigecycline	0.25	0.5	0.06 - 2	99.4%	-	0.6%
TMP-SMX	≤ 0.12	8	≤ 0.12 - >8	88.9%	-	11.1%
Vancomycin	1	1	≤ 0.25 - 4	99.9%	0.1%	0.0%

Table 2. Vancomycin MIC distributions for CA-MRSA and HA-MRSA.

Genotype, Study Year	Number (%) at each Vancomycin MIC				
	≤ 0.25	0.5	1	2	4
CA-MRSA					
2007 (n=76)	17 (22.4)	59 (77.6)			
2008 (n=75)	17 (22.7)	58 (77.3)			
2009 (n=74)	8 (10.8)	64 (86.5)	2 (2.7)		
2010 (n=85)	11 (12.9)	74 (87.1)			
2011 (n=56)	22 (39.3)	34 (60.7)			
2012 (n=49)	27 (55.1)	29 (40.8)	2 (4.1)		
HA-MRSA					
2007 (n=305)	5 (1.6)	22 (7.2)	274 (89.8)	4 (1.3)	
2008 (n=188)	18 (9.6)	161 (85.6)	8 (4.3)	1 (0.5)	
2009 (n=152)	14 (9.2)	131 (86.2)	7 (4.6)		
2010 (n=131)	9 (6.9)	116 (88.5)	6 (4.6)		
2011 (n=92)	13 (14.1)	79 (85.9)			
2012 (n=68)	18 (26.5)	50 (73.5)			

0/31, 1/230 and 9/29 MRSA with vancomycin MICs of 0.5, 1 and 2 µg/ml, respectively, were identified as hVISA.

Antibiotic	All MRSA (n=1391)			% of Isolates per Category		
	MIC ₅₀	MIC ₉₀	MIC Range	S	I	R
Cefazolin	64	>128	1 - >128	-	-	100.0% ^a
Ciprofloxacin	>16	>16	0.12 - >16	14.9%	0.3%	84.8%
Clarithromycin	>16	>16	≤ 0.25 - >16	13.0%	0.1%	86.9%
Clindamycin	0.5	>8	≤ 0.25 - >8	50.0%	0.1%	49.9%
Daptomycin	0.25	0.25	0.06 - 2	99.9%	-	0.1%
Levofloxacin	>32	>32	0.12 - >32	14.1%	0.0%	85.9%
Linezolid	2	2	≤ 0.12 - 4	100.0%	-	-
Moxifloxacin	8	>16	$\leq $			